Drug Interactions in Infectious Diseases
The revised and up-to-date third edition of Drug Interactions in Infectious Diseases delivers a text that will enhance your clinical knowledge of the complex mechanisms, risks, and consequences of drug interactions associated with antimicrobials, infectio
- PDF / 5,593,703 Bytes
- 698 Pages / 439.37 x 666.142 pts Page_size
- 48 Downloads / 193 Views
For further volumes: http://www.springer.com/series/7646
wwwwwwwwwwwww
Stephen C. Piscitelli • Keith A. Rodvold Manjunath P. Pai Editors
Drug Interactions in Infectious Diseases Third Edition
Editors Stephen C. Piscitelli Clinical Pharmacology Infectious Diseases GlaxoSmithKline Research Triangle Park NC, USA [email protected]
Keith A. Rodvold College of Pharmacy (M/C 886) University of Illinois at Chicago Chicago, IL, USA [email protected]
Manjunath P. Pai Albany College of Pharmacy and Health Sciences Albany, NY, USA [email protected]
ISBN 978-1-61779-212-0 e-ISBN 978-1-61779-213-7 DOI 10.1007/978-1-61779-213-7 Springer New York Dordrecht Heidelberg London Library of Congress Control Number: 2011934048 © Springer Science+Business Media, LLC 2011 All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Humana Press, c/o Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights. While the advice and information in this book are believed to be true and accurate at the date of going to press, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein. Printed on acid-free paper Humana Press is part of Springer Science+Business Media (www.springer.com)
Foreword
Over the past decade, the prognosis for patients with many life threatening infections has improved dramatically. For patients with HIV infection, systemic fungal diseases, parasitic diseases, and highly resistant bacteria, we have new drugs and new strategies for eradicating infections even in our patients with the most devastating underlying morbidities. Thus, for patients who are receiving immunosuppressive therapy to combat cancer or transplant rejection or autoimmune disease, and for patients with multisystem injury due to trauma or cardiovascular disease or other processes, we can succeed in preventing or treating infections that most often had fatal consequences a decade ago. Health care providers are well aware that drugs are only effective and safe if administered with tactical and strategic planning. The right dose, given at the right time, to the right patient is a foundation for safe, error free care. However, determining the right dose and the right time is not easy in complex patients who have fluctuating renal and hepatic function, rapidly changing vol
Data Loading...
